• Tonix published a medical research presentation outlining TNX-4800, a long-acting, bactericidal human monoclonal antibody being developed to prevent Lyme disease in US volunteers.
• Phase 1 study in healthy adults was completed, with no significant clinical or laboratory safety signals reported; pharmacokinetics supported extended half-life from engineered Fc domain.
• Program planning now centers on an adaptive Phase 2 field study, pending FDA agreement; manufacturing of GMP material is underway with initiation targeted for 1H 2027.
• Proposed dosing is subcutaneous administration in spring with booster at two months, with expected protection within two days for at least six months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.